



CELLARES

Accelerating Access to Life-Saving Cell Therapies

Tuesday, October 17 2023, NASEM

Fabian Gerlinghaus, Co-Founder & CEO



Cellares is the World's First Integrated Development and Manufacturing Organization (IDMO)



Vertical Integration

Advanced Technologies + Global Manufacturing Services




Cell Shuttle™

Compact automation enables concurrent processing of up to 16 batches and 90% reduction in labor and facility size



Cartridge

Closing and automating the process reduces process failure rates by 75% compared with open and manual methods



Software

Powerful and flexible software supports 90% of allogeneic and autologous cell therapy modalities

ADVANCED TECHNOLOGIES



MANUFACTURING SERVICES



South San Francisco (CA) Preclinical & Clinical Services / Technology Development

- 57,000 ft²
- cGMP-ready in H1/2024
- 2 Cell Shuttles (capacity)
- 1,600 patient doses per year (based on a 7 day process)



Bridgewater (NJ) Preclinical, Clinical & Commercial Services

- 118,000 ft²
- cGMP-ready in H2/2024
- 50 Cell Shuttles (capacity)
- 40,000 patient doses per year (based on a 7 day process)

Technology Integration

The Cell Shuttle is functionally equivalent to ~100 benchtop instruments



ENRICHMENT



SELECTION



ACTIVATION



TRANSFECTION




TRANSDUCTION



EXPANSION



FORMULATION



16 batches processed in parallel



75% fewer process failures



90% less labor required




90% less facility space required



90% of modalities supported (auto & allo)




Fully Automated End-to-End Runs on the Cell Shuttle Far Exceeded the Release Specifications for Commercial CAR-T Products



Cellares
End-to-End Brochure

Visit our website to
[download](#)

Enabling Commercial Scale Manufacturing of Cell Therapies



INTEGRATED AUTOMATION

All unit operations in one Consumable Cartridge

+




HIGH-THROUGHPUT

Up to 16 cartridges for multi-product, concurrent manufacturing

=

Annual batches per Cell Shuttle




SCALABILITY

Up to 2,800 batches per Cell Shuttle per year

Our Mission: Meet Total Patient Demand Globally


IDMO Smart Factories can produce 10 times more cell therapy batches per year than conventional CDMO facilities, with the same footprint and the same workforce



118,000 ft²
Smart Factory Space

>40K

Capacity in batches per year
(based on a 7 days autologous process)




Only 6 months
Time to tech transfer

Choosing Cellares Means Choosing the IDMO Advantage

Flexibility

90% of cell therapy modalities supported



90%

Supported cell therapy modalities

SUPPORTED APPLICATIONS

- ✓ Autologous & Allogeneic
- ✓ CAR-T, HSC, TCR, NK, TIL, Treg, $\gamma\delta$ T cells

Speed


Only 6 months to
tech transfer



Partner with Cellares to automate and transfer a manual process to the Cell Shuttle in 6 months. Every tech transfer thereafter is instant to any other Cell Shuttle in any other Smart Factory in the world.


Cost Savings

50% lower price per batch compared
with conventional CDMOs



Quality

75% reduction in process failure rates




Unlimited Capacity

10x increase in
productivity & scalability

Total Cellares IDMO Capacity in autologous doses per year (2024-2027)

Cellares supports both autologous and allogeneic cell therapy processes.






Join the IDMO Revolution

Technology Adoption Partnership (TAP)

TAP is a fast and low-risk opportunity to automate and transfer partner's cell therapy process onto the Cell Shuttle



Bristol Myers Squibb has Joined Cellares' Technology Adoption Partnership (TAP)



Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform

- ✓ Cellares to provide proof-of-concept manufacturing for a key BMS CAR-T cell therapy
- ✓ Cellares' proprietary Cell Shuttle is a cost-efficient, reliable, fully automated, and highly scalable manufacturing solution
- ✓ Bristol Myers Squibb is the latest company to join Cellares' TAP program to evaluate potential benefits in meeting patient demand, lowering process failure rates, lowering manufacturing costs, and accelerating scale-out

Unlock the Full Potential of Your Cell Therapy

Contact bd@cellares.com to start the conversation

